27888-44-4
Chemical Structure
C22-Ceramide (d18:1/22:0)
Synonym(s): N-Behenoyl-D-erythro-sphingosine; C22-Ceramide; Cer d18:1/22:0
- CAS No.: 27888-44-4
- Formula:C40H79NO3
- Molecular Weight:622.06
IUPAC Name: N-((2S,3R,E)-1,3-dihydroxyoctadec-4-en-2-yl)docosanamide
InChIKey: KEPQASGDXIEOIL-GLQCRSEXSA-N
SMILES: CCCCCCCCCCCCCCCCCCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O
Biological Activity: C22-Ceramide (d18:1/22:0) (N-Behenoyl-D-erythro-sphingosine) is an ultra-long-chain ceramide containing a C22:0 behenoyl acyl chain. C22-Ceramide can be glycosylated via CGT-3 to form C22 glucosylceramide (C22 GlcCer), which in turn maintains clathrin membrane localization and lysosomal homeostasis, inhibits TOR signaling and promotes SKN-1 activation, thereby enhancing oxidative stress resistance and extending the lifespan of C. elegans. C22-Ceramide can be used in research on cardiometabolic diseases such as type 2 diabetes, obesity, dyslipidemia, coronary artery disease and thin-cap fibroatheroma (TCFA), as well as oxidative stress and aging-related studies[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
C22-Ceramide (d18:1/22:0) | 99.89% | C22-Ceramide (d18:1/22:0) (N-Behenoyl-D-erythro-sphingosine) is an ultra-long-chain ceramide containing a C22:0 behenoyl acyl chain. C22-Ceramide can be glycosylated via CGT-3 to form C22 glucosylceramide (C22 GlcCer), which in turn maintains clathrin membrane localization and lysosomal homeostasis, inhibits TOR signaling and promotes SKN-1 activation, thereby enhancing oxidative stress resistance and extending the lifespan of C. elegans. C22-Ceramide can be used in research on cardiometabolic diseases such as type 2 diabetes, obesity, dyslipidemia, coronary artery disease and thin-cap fibroatheroma (TCFA), as well as oxidative stress and aging-related studies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Aslan İ, et al. Sphingolipidomic profile and HDL subfractions in obese dyslipidemic type 2 diabetic patients. Prostaglandins & other lipid mediators. 2023 Jun;166:106719.
- [2]. Liu H, et al. Endogenous Ceramide 24:1 Constrains Th17-Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2026 May;13(29):e20695. [Content Brief]
- [3]. Gong Y, et al. Identification of Plasma Lipidomic Signatures Associated with Coronary Plaque Vulnerability. Journal of cardiovascular translational research. 2025 Oct;18(5):1019-1031.
- [4]. Wang F, et al. Saturated very long chain fatty acid configures glycosphingolipid for lysosome homeostasis in long-lived C. elegans. Nat Commun. 2021;12:5073.
